Cargando…

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens

Patients’ experience during treatment may affect treatment adherence. Our aim was to assess the impact of patient-reported outcomes (PROs) on adherence to different anti-hepatitis C virus (HCV) regimens. Clinical, demographic, and PRO data (short form-36 [SF-36], chronic liver disease questionnaire-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Younossi, Zobair M., Stepanova, Maria, Henry, Linda, Nader, Fatema, Younossi, Youssef, Hunt, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956799/ https://www.ncbi.nlm.nih.gov/pubmed/27428205 http://dx.doi.org/10.1097/MD.0000000000004151

Ejemplares similares

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
por: Younossi, Zobair M, et al.
Publicado: (2012)

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
por: Younossi, Zobair, et al.
Publicado: (2017)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care
por: Younossi, Zobair M., et al.
Publicado: (2016)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
por: Golabi, Pegah, et al.
Publicado: (2017)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study
por: Liu, Zhenhua, et al.
Publicado: (2023)

The response of hepatitis B virus genotype to interferon is associated with a mutation in the interferon-stimulated response element
por: Guo, Yanan, et al.
Publicado: (2019)

Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B
por: Buti, Maria, et al.
Publicado: (2021)

Hepatitis C Virus Infection: Looking for Interferon Free Regimens
por: González-Moreno, J., et al.
Publicado: (2013)

Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs
por: Lee, Seung Ho, et al.
Publicado: (2017)

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
por: Birerdinc, Aybike, et al.
Publicado: (2012)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
por: Chang, Christine Y., et al.
Publicado: (2017)

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report
por: Baik, Su Jung, et al.
Publicado: (2016)

Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report
por: Liu, Yu, et al.
Publicado: (2022)

The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
por: Paik, James M., et al.
Publicado: (2023)

Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study
por: Younossi, Zobair M., et al.
Publicado: (2016)

Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation
por: Cholongitas, Evangelos, et al.
Publicado: (2017)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens
por: Vasanthakumar, Aparna, et al.
Publicado: (2018)

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Younossi, Zobair M., et al.
Publicado: (2021)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis
por: Stepanova, Maria, et al.
Publicado: (2015)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy
por: Geng, Yan, et al.
Publicado: (2016)

Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case Report
por: Hsiao, Chien-Hao, et al.
Publicado: (2015)

Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review
por: Miyasaka, Akio, et al.
Publicado: (2020)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Improved Efficacy of a Pegylated Interferon-α-2a Stepwise Optimization Treatment Strategy in the Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Patients
por: Zhou, Pu, et al.
Publicado: (2015)

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)
por: Pires de Mello, Camilly P., et al.
Publicado: (2018)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pj0trf23gj11con16qe08oklku